Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pipeline Watch: 16 Japanese Approvals And Nine Phase III Trial Readouts

Executive Summary

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

You may also be interested in...



Galderma Readies Its First Therapeutic Biologic For Two US Launches In 2024

Galderma said its IL-31 receptor alpha inhibitor nemolizumab succeeded in two Phase III atopic dermatitis trials, advancing the firm’s long-term goal of moving past topical dermatology drugs.

Galderma Hopes To Break Into Prurigo Nodularis Market, But May Face Rivals

The dermatology specialist announced positive results from the OLYMPIA 2 trial of nemolizumab, but Sanofi and Regeneron are already pursuing a similar indication for Dupixent. 

Executives On The Move: Joseph Papa Joins Emergent BioSolutions As CEO Among Other Industry Moves

Recent moves within the industry include changes at the top for Ocular Therapeutix and Rayzebio, plus a new CEO for Bellicum Pharmaceuticals.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146170

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel